Update on the role of venetoclax and rituximab in the treatment of relapsed or refractory CLL
For the treatment of mature B cell malignancies including chronic lymphocytic leukemia (CLL), the last 5 years has brought major advances in the application of targeted therapies. Whilst monoclonal anti-CD20 agents such as rituximab have a central role in combination with traditional cytotoxic thera...
Na minha lista:
| Principais autores: | , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
SAGE Publishing
2019-05-01
|
| Colecção: | Therapeutic Advances in Hematology |
| Acesso em linha: | https://doi.org/10.1177/2040620719844697 |
| Tags: |
Sem tags, seja o primeiro a adicionar uma tag!
|